Government-Owned Inventions; Availability for Licensing, 32454 [2024-08986]
Download as PDF
<![CDATA[
32454
Federal Register / Vol. 89, No. 82 / Friday, April 26, 2024 / Notices
recovery. The rate cannot be lower than
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
Maturities’’ unless the Secretary waives
interest in whole or part, or a different
rate is prescribed by statute, contract, or
repayment agreement. The Secretary of
the Treasury may revise this rate
quarterly. The Department of Health and
Human Services publishes this rate in
the Federal Register.
The current rate of 121⁄2%, as fixed by
the Secretary of the Treasury, is certified
for the quarter ended March 31, 2024.
This rate is based on the Interest Rates
for Specific Legislation, ‘‘National
Health Services Corps Scholarship
Program (42 U.S.C. 254o(b)(1)(A))’’ and
‘‘National Research Service Award
Program (42 U.S.C. 288(c)(4)(B)).’’ This
interest rate will be applied to overdue
debt until the Department of Health and
Human Services publishes a revision.
David C. Horn,
Director, Office of Financial Policy and
Reporting.
[FR Doc. 2024–08939 Filed 4–25–24; 8:45 am]
BILLING CODE 4150–04–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852 by contacting
Dawn Taylor-Mulneix at 301–451–8021
or dawn.taylor-mulneix@nih.gov. A
signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
20:31 Apr 25, 2024
Jkt 262001
Human Monoclonal Antibodies That
Target the RH5 Complex of Blood-Stage
Plasmodium Falciparum
Description of Technology
249 million people were afflicted with
malaria in 2022. There are five
Plasmodium parasite species that cause
malaria in humans. Of the five,
Plasmodium falciparum causes most of
the incidence of human disease. Most
advanced malaria vaccine candidates
can confer only partial, short-term
protection in malaria-endemic areas.
The pathogenesis of malaria is
associated with blood-stage infection
and antibodies specific to the parasite
blood-stage antigens may be able to
control parasitemia. To address this
public health need, NIAID inventors
have developed 35 human monoclonal
antibodies that target the RH5 complex
of blood-stage Plasmodium falciparum
and were found to have potent activity
in in vitro growth inhibition assays.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Method of prophylactic and/or
therapeutic treatment by targeting
blood-stage antigens of Plasmodium.
National Institutes of Health
AGENCY:
SUPPLEMENTARY INFORMATION:
Technology description follows:
Competitive Advantages
• Most other commercially available
antibodies targeting against Plasmodium
target circumsporozoite protein (CSP)
present in the sporozoite stage. These
novel antibodies instead target a
conserved and essential antigen present
in the blood stage: RH5.
• These monoclonal antibodies can
be used alone or in combination with
existing antibodies.
Developmental Stage
• Pre-clinical.
Inventors: Joshua Tan, Ph.D.,
Lawrence Wang, Ph.D. and Andrew
Cooper, Ph.D., all of NIAID.
Publications: Wang, L., Cooper, A., et
al. ‘‘Natural malaria infection elicits rare
but potent neutralizing antibodies to the
blood-stage antigen RH5.’’ bioRxiv.
https://www.biorxiv.org/content/
10.1101/2023.10.04.560669v1, October
06, 2023.
Intellectual Property: HHS Reference
No. E–014–2023; Provisional Patent
Application No.: 63/468,740.
Licensing Contact: To license this
technology, please contact Dawn TaylorMulneix at 301–451–8021 or
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
dawn.taylor-mulneix@nih.gov, and
reference E–014–2023.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. For
collaboration opportunities, please
contact Dawn Taylor-Mulneix at 301–
451–8021 or dawn.taylor-mulneix@
nih.gov.
Dated: April 19, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2024–08986 Filed 4–25–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket Number USCG–2024–0281]
Operational Adjustments Resulting
From Workforce Shortages
Coast Guard, DHS.
Notice and request for
comments.
AGENCY:
ACTION:
We are requesting your
comments on planned actions that will
allow the Coast Guard to prioritize
lifesaving missions and protection of the
Marine Transportation System in light
of current personnel shortages. Like
other military services, the Coast Guard
is facing an unprecedented workforce
shortage that is impacting Service
readiness. The current and forecasted
extent of the shortage is prompting
significant actions to best protect the
American public and maintain Service
readiness. If actions are not taken to
adjust operations, we can anticipate
longer-term impacts to mission
effectiveness and increased risk to our
service members, as well as to
commercial mariners and private
boaters. In addition to leveraging
technology and enhancing recruitment
and retention efforts, operational
adjustments must be executed within
the existing response system while
maintaining standards and an adherence
to core mission execution. These
adjustments fall into two categories:
First, in regions where multiple units
could respond if they were resourced
appropriately, boats and people will be
consolidated at one or more units to
ensure a robust response. Secondly, in
areas where the Coast Guard operates
SUMMARY:
E:\FR\FM\26APN1.SGM
26APN1
]]>Agencies
[Federal Register Volume 89, Number 82 (Friday, April 26, 2024)]
[Notices]
[Page 32454]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-08986]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by contacting Dawn Taylor-Mulneix at
301-451-8021 or [email protected]. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Human Monoclonal Antibodies That Target the RH5 Complex of Blood-Stage
Plasmodium Falciparum
Description of Technology
249 million people were afflicted with malaria in 2022. There are
five Plasmodium parasite species that cause malaria in humans. Of the
five, Plasmodium falciparum causes most of the incidence of human
disease. Most advanced malaria vaccine candidates can confer only
partial, short-term protection in malaria-endemic areas. The
pathogenesis of malaria is associated with blood-stage infection and
antibodies specific to the parasite blood-stage antigens may be able to
control parasitemia. To address this public health need, NIAID
inventors have developed 35 human monoclonal antibodies that target the
RH5 complex of blood-stage Plasmodium falciparum and were found to have
potent activity in in vitro growth inhibition assays.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
Method of prophylactic and/or therapeutic treatment by
targeting blood-stage antigens of Plasmodium.
Competitive Advantages
Most other commercially available antibodies targeting
against Plasmodium target circumsporozoite protein (CSP) present in the
sporozoite stage. These novel antibodies instead target a conserved and
essential antigen present in the blood stage: RH5.
These monoclonal antibodies can be used alone or in
combination with existing antibodies.
Developmental Stage
Pre-clinical.
Inventors: Joshua Tan, Ph.D., Lawrence Wang, Ph.D. and Andrew
Cooper, Ph.D., all of NIAID.
Publications: Wang, L., Cooper, A., et al. ``Natural malaria
infection elicits rare but potent neutralizing antibodies to the blood-
stage antigen RH5.'' bioRxiv. https://www.biorxiv.org/content/10.1101/2023.10.04.560669v1, October 06, 2023.
Intellectual Property: HHS Reference No. E-014-2023; Provisional
Patent Application No.: 63/468,740.
Licensing Contact: To license this technology, please contact Dawn
Taylor-Mulneix at 301-451-8021 or [email protected], and
reference E-014-2023.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Dawn Taylor-Mulneix at 301-451-8021 or
[email protected].
Dated: April 19, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-08986 Filed 4-25-24; 8:45 am]
BILLING CODE 4140-01-P
